Hologic INC 8-K filings

Hologic, Inc. has completed its acquisition by funds managed by Blackstone and TPG, valued at up to $79 per share, with Joe Almeida appointed as the new CEO.

Hologic has secured all necessary regulatory approvals for its acquisition by Blackstone and TPG, with the transaction expected to close on April 7, 2026.

Hologic, Inc. stockholders approved the merger agreement with Blackstone and TPG, though they rejected the advisory compensation proposal for executives.

Hologic reports mixed Q1 FY26 financial results as stockholders prepare to vote on the proposed acquisition by Blackstone and TPG.

Hologic, Inc. addresses stockholder lawsuits over its merger proxy, announces a prolonged stop-ship for a key breast biopsy product, and settles BioZorb litigation.

Hologic, Inc. announced the approval of a revised Restricted Stock Unit Award Agreement by its Compensation Committee, outlining new vesting schedules and change-in-control provisions.

Hologic, Inc. announced robust financial results for its fiscal fourth quarter 2025, alongside a definitive agreement to be acquired by Blackstone and TPG Capital for up to $79 per share.

Hologic, Inc. announced a definitive agreement to be acquired by funds managed by Blackstone and TPG for up to $79 per share, including a contingent value right.

Hologic, Inc. announced an amendment to extend the employment agreement of its Chairman, President, and CEO, Stephen P. MacMillan.

Hologic, Inc. reported third-quarter fiscal 2025 revenue of $1,023.8 million and non-GAAP diluted EPS of $1.08, both surpassing guidance, while also refinancing its term loan and revolving credit facility.

Hologic, Inc. has successfully refinanced its term loan and revolving credit facilities, securing $2.419 billion in new financing and extending its debt maturity profile to July 2030, while also gaining additional covenant flexibility.

Hologic reports Q2 fiscal 2025 revenue of $1,005.3 million, slightly exceeding guidance, with non-GAAP EPS of $1.03 at the high end of guidance, while maintaining annual revenue guidance but lowering GAAP and non-GAAP EPS guidance.

Hologic, Inc. has appointed Wayde McMillan, Chief Financial Officer of Solventum Corporation, to its Board of Directors, effective April 4, 2025, increasing the board size from eight to nine members.

Hologic's General Counsel, John Griffin, will retire in 2025, transitioning to Special Advisor, with Anne Liddy stepping into the General Counsel role effective May 1, 2025.

Hologic's annual stockholder meeting resulted in the election of all director nominees, advisory approval of executive compensation, ratification of Ernst & Young as the company's auditor, and advisory approval of a proposal to replace supermajority voting provisions.

Hologic reports Q1 2025 financial results with revenue slightly up, but lowers full-year GAAP EPS guidance while maintaining non-GAAP EPS guidance.

Hologic reported preliminary first-quarter fiscal 2025 revenue of $1,021.8 million, a 0.9% increase year-over-year, aligning with guidance on a constant currency basis.

Hologic, Inc. announces the retirement of board members Sally W. Crawford and Scott T. Garrett at the upcoming 2025 Annual Meeting of Stockholders.

Hologic has appointed Martin Madaus to its Board of Directors, increasing the board size from nine to ten members, effective December 6, 2024.

Hologic Inc.'s Compensation Committee has approved new Performance Stock Unit (PSU) award agreements for fiscal year 2025, with vesting tied to return on invested capital, relative total shareholder return, and free cash flow goals.

Hologic announced strong financial results for the fourth quarter and fiscal year 2024, driven by growth across its diagnostics and breast health segments, and outlined its strategy for continued growth in fiscal year 2025.

Hologic's Board of Directors has authorized a new stock repurchase program of up to $1.5 billion, adding to an existing $190 million authorization.

Hologic reported strong financial results for the third quarter of fiscal year 2024, exceeding guidance with revenue of $1,011.4 million and non-GAAP diluted EPS of $1.06.

Hologic reported strong second-quarter results, exceeding guidance for both revenue and non-GAAP earnings per share, and raised its full-year outlook.

Hologic reported second-quarter results that exceeded guidance, driven by strong performance in Diagnostics and Surgical divisions, and raised its full-year revenue and EPS outlook.

Hologic's annual meeting saw the election of all director nominees, advisory approval of executive compensation, and ratification of Ernst & Young as the independent auditor.

Hologic reported strong first-quarter results, surpassing guidance for both revenue and earnings, and increased its full-year outlook.

Hologic, Inc. announces that board member Namal Nawana will not seek re-election at the 2024 Annual Meeting, reducing the board size to nine directors.